Clinical Trials Logo

Cardiomyopathy, Dilated clinical trials

View clinical trials related to Cardiomyopathy, Dilated.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT04405804 Enrolling by invitation - Acute Heart Failure Clinical Trials

Early Administration of Ivabradine in Children With Heart Failure

EASI-Child
Start date: June 20, 2020
Phase: Phase 2
Study type: Interventional

This is a monocentric, prospective, single arm, not for profit study. It is designed to study the early use of ivabradine in patients with dilated cardiomyopathy and Ejection Fraction (EF) < 45%.

NCT ID: NCT03527342 Enrolling by invitation - Clinical trials for Hypertrophic Cardiomyopathy

Sahlgrenska Cardiomyopathy Project

Start date: June 1, 2018
Phase:
Study type: Observational [Patient Registry]

This is a joint project by Sahlgrenska University Hospital: Sahlgrenska, Östra and Mölndal. Our objective is to diagnose and map patients with well phenotyped cardiomyopathies (CMP) including in depth clinical and molecular phenotyping to enable earlier and specific treatment. The project will serve as: 1. resource for diagnostic and therapeutic trials 2. common biomaterial bank 3. resource for detailed molecular analyses on patients' biomaterials and patient specific symptoms and examination results

NCT ID: NCT02440217 Enrolling by invitation - Type 2 Diabetes Clinical Trials

Myocardial Metabolism in Patients With Dilated Cardiomyopathy

Start date: May 2015
Phase: N/A
Study type: Observational

Dilated cardiomyopathy (DCM) is characterized by a metabolic shift from fat to carbohydrates and failure to increase myocardial glucose uptake in response to workload increments. The investigators aimed at verifying whether this pattern is influenced by the presence of abnormal glucose tolerance (AGT).

NCT ID: NCT02413450 Enrolling by invitation - Clinical trials for Hypertrophic Cardiomyopathy (HCM)

Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias

Start date: August 2013
Phase:
Study type: Observational [Patient Registry]

Human induced pluripotent stem cells (hiPSCs) have driven a paradigm shift in the modeling of human disease; the ability to reprogram patient-specific cells holds the promise of an enhanced understanding of disease mechanisms and phenotypic variability, with applications in personalized predictive pharmacology/toxicology, cell therapy and regenerative medicine. This research will collect blood or skin biopsies from patients and healthy controls for the purpose of generating cell and tissue models of Mendelian heritable forms of heart disease focusing on cardiomyopathies, channelopathies and neuromuscular diseases. Cardiomyocytes derived from hiPSCs will provide a ready source of disease specific cells to study pathogenesis and therapeutics.